Uveitis

Tattoo ink inflammation increasingly triggers uveitis, often harming vision and requiring systemic steroids.

Findings from the retrospective, observational study support the potential anti-inflammatory benefits of the drug class.

A rare case of tubulointerstitial nephritis and uveitis syndrome in a teenager highlights the importance of multidisciplinary diagnosis and management.

Kiora Pharmaceuticals secures a patent for KIO-104, enhancing treatment options for ocular diseases and extending market exclusivity until 2043.

New clinical guidance for anterior and posterior uveitis was published by a research team from the University of Bristol.

The preclinical data was presented during the 2025 ARVO meeting.

The findings of this model support KIO-104 as a promising therapeutic candidate for both the prevention and treatment of PVR.

Arctic Vision has a commercial collaboration agreement with Santen Pharmaceutical Co., Ltd. to commercialize ARVN001 for the treatment of UME.

This research project, titled, “A Generalizable Deep Learning Platform for Unifying Quantification of Experimental Autoimmune Uveitis.”

ACELYRIN will not make any additional internal investment in developing izokibep.

ARVN001 is indicated for the treatment of uveitic macular edema (UME) and certain other ophthalmic indications under development.

Dr. Arepalli discussed a course focused on ocular conditions related to pregnancy and postpartum care, presented at the American Academy of Ophthalmology (AAO) meeting.

Steven Yeh, MD, discussed his recent presentation at the Retina Society meeting and shared what he is looking forward to presenting at this year's American Academy of Ophthalmology meeting held in Chicago, Illinois.

Brepocitinib is a potential first-in-class dual selective inhibitor of TYK2 and JAK1.

Lynn Hassman, MD, PhD, has received the Philip and Elaine Ellis New Investigator in Ophthalmology Research Award, and will focus on seeking treatment options for uveitis patients.

The results from the trial in China met both the primary and secondary endpoints with no serious adverse events or new safety signals.

Ashkan Abbey, MD, spoke with Modern Retina about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.

Danny Mammo, MD, sat down with Sydney M. Crago, Assistant Managing Editor of Ophthalmology Times and Modern Retina, to discuss the effect of suprachoroidal triamcinolone acetonide in non-infectious uveitis, patients which he is presenting at the American Society of Retina Specialists (ASRS) meeting held in Stockholm, Sweden.

Michael Singer, MD, spoke with Modern Retina about his presentation of first time data from the CALM Registry at Clinical Trials at the Summit meeting being held in Park City, Utah on June 8, 2024.

The UME module adds to the list of ophthalmic diseases available in the dataset.

David Almeida, MD, PhD, MBA, presented on gene therapy associated uveitis at the 2024 Retina World Congress meeting in Fort Lauderdale, Florida.

In a presentation at the Association for Research in Vision and Ophthalmology’s 2024 Annual Meeting in Seattle, Washington, researchers used Google’s recommended top 8 uveitis patient educational websites in the study to determine whether ChatGPT 4.0 could be used as a uveitis patient online resource.